AxoGen, Inc. (AXGN) |
| 38.77 -0.72 (-1.82%) 07-14 16:00 |
| Open: | 39.49 |
| High: | 39.99 |
| Low: | 38.23 |
| Volume: | 1,167,257 |
| Market Cap: | 2,062(M) |
| PE Ratio: | 102.03 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 46.95 |
| Resistance 1: | 43.62 |
| Pivot price: | 43.55 |
| Support 1: | 38.23 |
| Support 2: | 31.81 |
| 52w High: | 46.95 |
| 52w Low: | 11.25 |
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
| EPS | -0.600 |
| Book Value | 4.610 |
| PEG Ratio | 99.04 |
| Gross Profit | 3.359 |
| Profit Margin (%) | -13.21 |
| Operating Margin (%) | -4.61 |
| Return on Assets (ttm) | -2.3 |
| Return on Equity (ttm) | -18.0 |
Mon, 06 Jul 2026
What Axogen (AXGN)'s Russell Index Removal Means For Shareholders - simplywall.st
Mon, 06 Jul 2026
What Axogen (AXGN)'s Russell Index Removal Means For Shareholders - Sahm
Fri, 26 Jun 2026
Axogen (AXGN) director John Johnson receives 4,392 RSUs valued at $185,000 - Stock Titan
Fri, 26 Jun 2026
Axogen (AXGN) director receives 4,392 restricted stock units in annual equity grant - Stock Titan
Fri, 26 Jun 2026
Axogen (AXGN) director receives 4,392 RSUs in $185,000 equity grant - Stock Titan
Thu, 25 Jun 2026
AXGN Forecast — Price Target — Prediction for 2027 - TradingView
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |